China's new Alzheimer's drug completes phase 3 clinical trial
SHANGHAI, July 17 (Xinhua) -- A Chinese research group on Tuesday announced progress in developing a drug to treat Alzheimer's disease.
GV-971 was developed by Ocean University of China, Shanghai Institute of Materia Medica under Chinese Academy of Sciences and Green Valley Pharmaceutical Co., Ltd, after a 21-year study.
A phase three clinical trial is the last test before reaching the market.
In the trial, participants took 450 mg GV-971 orally twice a day for 36 weeks, which proved effective in improving cognition.